D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: A pilot randomized clinical trial

Neuropsychopharmacology

Volumn 39, Issue 5, 2014, Pages 1052-1058

  Difede, Joann ^a,b   Cukor, Judith ^a,b   Wyka, Katarzyna ^a   Olden, Megan ^a,b   Hoffman, Hunter ^c   Lee, Francis S ^a,b   Altemus, Margaret ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^c University of Washington   (United States)

Author keywords

D cycloserine; exposure therapy; post traumatic stress disorder; terrorism; translational research; virtual reality

Indexed keywords

CYCLOSERINE; PLACEBO; PSYCHOTROPIC AGENT;

ANGER; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CLINICIAN ADMINISTERED PTSD SCALE; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEAR; FEMALE; FOLLOW UP; HUMAN; MALE; NERVE CELL PLASTICITY; PILOT STUDY; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; REINFORCEMENT; REMISSION; SENSITIVITY ANALYSIS; SLEEP; STATE-TRAIT ANGER EXPRESSION INVENTORY; SYMPTOM; TREATMENT OUTCOME; VIRTUAL REALITY EXPOSURE THERAPY; ADJUVANT CHEMOTHERAPY; ADULT; AGED; BEHAVIOR THERAPY; BLOOD; CHRONIC DISEASE; DRUG EFFECTS; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; STRESS DISORDERS, POST-TRAUMATIC; TIME;

ADULT; AGED; ANGER; CHEMOTHERAPY, ADJUVANT; CHRONIC DISEASE; CYCLOSERINE; DEPRESSION; DOUBLE-BLIND METHOD; EXTINCTION, PSYCHOLOGICAL; FEAR; FEMALE; HUMANS; IMPLOSIVE THERAPY; MALE; MIDDLE AGED; PILOT PROJECTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; SLEEP; STRESS DISORDERS, POST-TRAUMATIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896388390     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2013.317     Document Type: Article

References (36)

1. Alonso J, Petukhova M, Vilagut G, Chatterji S, Heeringa S, Ustun TB et al (2011). Days out of role due to common physical and mental conditions: results from the WHO World Mental Health surveys. Mol Psychiatry 16: 1234-1246.
2. Baron H, Epstein IG, Mulinos MG, Nair KG (1956). Absorption, distribution, and excretion of cycloserine in man. Antibiotics Annual 16: 1234-1246.
3. Beck AT, Steer RA, Brown GK (1996). Manual for the Beck Depression Inventory-II. Psychological Corporation: San Antonio, TX, USA.
4. Blake DD, Weathers FW, Nagy LM, Kalopek DG, Charney DS, Keane TM (1998). Clinician-Administered PTSD Scale for DSMIV. Boston VA Medical Center, National Center for Posttraumatic Stress Disorder, Behavioral Science Division: Boston, MA, USA.
5. Bobula B, Hess G (2008). Antidepressant treatments-induced modifications of glutamatergic transmission in rat frontal cortex. Pharmacol Rep 60: 865-871.
6. Boje KM, Wong G, Skolnick P (1993). Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res 603: 207-214. (Pubitemid 23069216)
7. Calabrese F, Guidotti G, Molteni R, Racagni G, Mancini M, Riva MA (2012). Stress-induced changes of hippocampal NMDA receptors: modulation by duloxetine treatment. PLoS One 7: e37916.
8. Davis M, Ressler K, Rothbaum BO, Richardson R (2006). Effects of D-cycloserine on extinction: translation from preclinical to clinical work. Biol Psychiatry 60: 369-375. (Pubitemid 44215855)
9. de Kleine RA, Hendriks GJ, Kusters WJ, Broekman TG, van Minnen A (2012). A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder. Biol Psychiatry 71: 962-968.
10. Dedert EA, Calhoun PS, Watkins LL, Sherwood A, Beckham JC (2010). Posttraumatic stress disorder, cardiovascular, and metabolic disease: a review of the evidence. Ann Behav Med 39: 61-78.
11. Difede J, Cukor J, Jayasinghe N, Patt I, Jedel S, Spielman L et al (2007). Virtual reality exposure therapy for the treatment of posttraumatic stress disorder following September 11, 2001. J Clin Psychiatry 68: 1639-1647. (Pubitemid 350247492)
12. First MB, Spitzer RL, Williams JBW, Gibbon M (1997). Structured Clinical Interview for DSM-IV SCID. American Psychiatric Association: Washington, DC, USA. Foa EB, Keane T, Friedman M (eds). (2000). Effective Treatments for PTSD: Practice guidelines from the International Society for Traumatic Stress Studies. Guilford Press: New York, NY, USA.
13. Foa EB, Kozak MJ (1986). Emotional processing of fear: exposure to corrective information. Psychol Bull 99: 20-35.
14. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P et al (2008). A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 63: 544-549.
15. Hidalgo RB, Davidson JR (2000). Posttraumatic stress disorder: epidemiology and health-related considerations. J Clin Psychiatry 61(Suppl 7): 5-13. (Pubitemid 30233559)
16. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K et al (2006). Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63: 298-304. (Pubitemid 43345354)
17. Hoge CW, Castro CA, Messer SC, McGurk D, Cotting DI, Koffman RL (2004). Combat duty in Iraq and Afghanistan, mental health problems, and barriers to care. N Engl J Med 351: 13-22. (Pubitemid 38857243)
18. Institute of Medicine (IOM) (2008). Treatment of Posttraumatic Stress Disorder: An Assessment of the Evidence. The National Academies Press: Washington DC, USA.
19. Kessler RC (2000). Posttraumatic stress disorder: the burden to the individual and to society. J Clin Psychiatry 61(Suppl 5): 4-12 discussion 13-14.
20. Kessler RC, Sonnega A, Bromet E, Hughes M, Nelson CB (1995). Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 52: 1048-1060.
21. Kosslyn SM, Cacioppo JT, Davidson RJ, Hugdahl K, Lovallo WR, Spiegel D et al (2002). Bridging psychology and biology: the analysis of individuals in groups. Am Psychol 57: 341-351.
22. Ledgerwood L, Richardson R, Cranney J (2003). Effects of D-cycloserine on extinction of conditioned freezing. Behav Neurosci 117: 341-349. (Pubitemid 36384252)
23. Litz BT, Salters-Pedneault K, Steenkamp MM, Hermos JA, Bryant RA, Otto MW et al (2012). A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder. J Psychiatr Res 46: 1184-1190.
24. Nowak G, Trullas R, Layer RT, Skolnick P, Paul IA (1993). Adaptive changes in the N-methyl-D-aspartate receptor complex after chronic treatment with imipramine and 1-aminocyclopropanecarboxylic acid. J Pharmacol Exp Ther 265: 1380-1386. (Pubitemid 23321045)
25. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA et al (2010). Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 67: 365-370.
26. Parsons TD, Rizzo AA (2008). Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: a meta analysis. J Behav Ther Exp Psychiatry 39: 250-261. (Pubitemid 351766757)
27. Quartermain D, Mower J, Rafferty MF, Herting RL, Lanthorn TH (1994). Acute but not chronic activation of the NMDA-coupled glycine receptor with D-cycloserine facilitates learning and retention. Eur J Pharmacol 257: 7-12. (Pubitemid 24178543)
28. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E et al (2004). Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61: 1136-1144. (Pubitemid 39463415)
29. Schottenbauer MA, Glass CR, Arnkoff DB, Tendick V, Gray S (2008). Nonresponse and dropout rates in outcome studies on PTSD: review and methodological considerations. Psychiatry Interpersonal Biological Processes 71: 134-168.
30. Spielberger C (1999). STAXI-2 State-Trait Anger Expression Inventory-2: Professional Manual. Psychological Assessment Resources: Odessa, FL, USA.
31. Spoormaker VI, Montgomery P (2008). Disturbed sleep in posttraumatic stress disorder: secondary symptom or core feature? Sleep Med Rev 12: 169-184.
32. Walker DL, Ressler KJ, Lu KT, Davis M (2002). Facilitation of conditioned fear extinction by systemic administration or intraamygdala infusions of D-cycloserine as assessed with fearpotentiated startle in rats. J Neurosci 22: 2343-2351. (Pubitemid 35386533)
33. Weathers FW, Litz FW, Herman DS, Huska JA, Keane TM (1993). The PTSD Checklist (PCL): reliability, validity, and diagnostic utility. Annual Meeting of the International Society for Traumatic Stress Studies. San Antonio, TX, USA.
34. Werner-Seidler A, Richardson R (2007). Effects of D-cycloserine on extinction: consequences of prior exposure to imipramine. Biol Psychiatry 62: 1195-1197. (Pubitemid 350029724)
35. Yule W (2001). Posttraumatic stress disorder in the general population and in children. J Clin Psychiatry 62(Suppl 17): 23-28. (Pubitemid 32720662)
36. Zimmerman JM, Maren S (2010). NMDA receptor antagonism in the basolateral but not central amygdala blocks the extinction of Pavlovian fear conditioning in rats. Eur J Neurosci 31: 1664-1670.